Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Asimadoline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Asimadoline: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALG11 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG11, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Galicaftor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Galicaftor: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALG10B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG10B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
Mecasermin Rinfabate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
3 August 2026
Mecasermin Rinfabate: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALG10 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG10, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALG9 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG9, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALG8 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG8, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALG6 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG6, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALG5 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG5, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALG3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALG2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
3 August 2026
A visual target evaluation report for ALG2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.